Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
An article from
Startup launches
Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
Published Aug. 11, 2026
Former Legend Biotech CEO Ying Huang is now the top executive at K2 Therapeutics, a startup in-licensing assets from across the globe.
Ying Huang, ex-Legend Biotech CEO, joins K2 Therapeutics as CEO. Firm targets 20 assets, raised $50M from MPM BioImpact, seeks…
Ying Huang resigns and Carvykti president Alan Bash is named interim CEO after Legend slides about 33%+ since June's $226 million…
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti.…
Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. | Legend Biotech's Ying Huang, Ph.D., resigned after…
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting…
Expedition Therapeutics disclosed the Series B in conjunction with dosing the first patient in its global Phase 2 for the DPP1…
Ying Huang's post-Legend life takes shape at K2, with $250M goal to license Asia assets
Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
Legend interim CEO talks rising competition as Carvykti maker posts first profit
Dark Horse Consulting Group Expands into China, Appoints Kang Liu as Senior Director, Head of China
Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
A scientist-turned-biotech executive is notching some wins, and enjoying it
